BLTE - Company ID 0001889109
BELITE BIO, INC trades as BLTE and has a market capitalization of $6.00 B, making it the #1292 largest US-listed company by market value. This page tracks BELITE BIO, INC through 194 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| 6-K | - | 2026-05-20 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| Insider trade | 4 | 2026-05-08 |
| Insider trade | 4 | 2026-05-07 |
| Insider trade | 4 | 2026-05-06 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-04 |
| Insider trade | 4 | 2026-05-01 |
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update · Enrollment was completed with 530 subjects.
Belite expects to complete the new drug application submission in the second quarter of 2026 · Rolling submission initiated under Breakthrough ...
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”) today announced topline results ...
The largest companies sharing BELITE BIO, INC's SEC industry classification (pharmaceutical preparations).
BELITE BIO, INC (BLTE) has a market capitalization of $6.00 B as of 2026-07-09, ranking #1292 among US-listed companies.
In its latest fiscal year BELITE BIO, INC reported a net loss of $77.61M.